User profiles for J.H. Ficker

Joachim H. Ficker

Paracelsus Medizinische Privatuniversität Nürnberg
Verified email at klinikum-nuernberg.de
Cited by 7947

[HTML][HTML] Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

WM Brueckl, JH Ficker, G Zeitler - BMC cancer, 2020 - Springer
Background Immune checkpoint inhibitors (ICI) either alone or in combination with chemotherapy
have expanded our choice of agents for the palliative treatment of non-small cell lung …

[HTML][HTML] German S3 guideline nonrestorative sleep/sleep disorders, chapter “Sleep-related breathing disorders in adults,” short version: German Sleep Society …

G Mayer, M Arzt, B Braumann, JH Ficker, I Fietze… - Somnologie, 2017 - Springer
1. What’s new? 2. Classification of sleep-related breathing disorders 2.1 Obstructive sleep
apnea 2.2 Central sleep apnea 2.3 Sleep-related hypoventilation/sleep-related hypoxemia 3. …

Continuous positive airway pressure treatment rapidly improves insulin sensitivity in patients with obstructive sleep apnea syndrome

…, T Lohmann, PC Konturek, JH Ficker - American journal of …, 2004 - atsjournals.org
The obstructive sleep apnea syndrome is typically associated with conditions known to
increase insulin resistance as hypertension, obesity, and diabetes. We investigated whether …

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a …

JA Wedzicha, M Decramer, JH Ficker… - The lancet Respiratory …, 2013 - thelancet.com
Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on
exacerbations in patients with severe and very severe chronic obstructive pulmonary …

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo …

…, D Koschel, S Blaas, H Wirtz, JH Ficker… - The Lancet …, 2021 - thelancet.com
Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …

Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort

…, S Leroy, JM Vergnon, JH Ficker… - European …, 2012 - Eur Respiratory Soc
The Endobronchial Valve for Emphysema Palliation Trial (VENT) was a multi-centre,
prospective, randomised, controlled trial conducted to evaluate the safety and effectiveness of …

Leptin and ghrelin levels in patients with obstructive sleep apnoea: effect of CPAP treatment

…, EG Hahn, T Lohmann, JH Ficker - European …, 2003 - Eur Respiratory Soc
Serum leptin and ghrelin levels were investigated in patients with obstructive sleep apnoea (OSA)
syndrome before and during continuous positive airways pressure (CPAP) treatment …

Endobronchial valve therapy in patients with homogeneous emphysema. Results from the IMPACT study

…, F Herth, K Darwiche, M Wagner, JH Ficker… - American journal of …, 2016 - atsjournals.org
Rationale: Endobronchial valves (EBVs) have been successfully used in patients with severe
heterogeneous emphysema to improve lung physiology. Limited available data suggest …

Radiological and clinical outcomes of using Chartis™ to plan endobronchial valve treatment

…, R Eberhardt, D Gompelmann, JH Ficker… - European …, 2013 - Eur Respiratory Soc
One-way endobronchial valves (EBVs) have been shown to relieve symptoms of emphysema,
particularly in patients without collateral ventilation (CV) between the target and adjacent …

The effect of continuous positive airway pressure treatment on insulin sensitivity in patients with obstructive sleep apnoea syndrome and type 2 diabetes

…, EG Hahn, PC Konturek, T Lohmann, JH Ficker - Respiration, 2004 - karger.com
… 27 Harsch IA, Pour Schahin S, Radespiel-Tröger M, Weintz O, Jahreiss H, Fuchs FS, Wiest
GH, Hahn EG, Lohmann T, Konturek PC, Ficker JH: Continuous positive airway pressure treat…